MICHAEL A DAVIES to Imidazoles
This is a "connection" page, showing publications MICHAEL A DAVIES has written about Imidazoles.
Connection Strength
1.084
-
Melanoma in 2017: Moving treatments earlier to move further forwards. Nat Rev Clin Oncol. 2018 02; 15(2):75-76.
Score: 0.390
-
Molecular approaches to tumor inhibition in melanoma. Clin Adv Hematol Oncol. 2015 Dec; 13(12):831-3.
Score: 0.340
-
Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. Lancet Oncol. 2018 02; 19(2):181-193.
Score: 0.098
-
Dabrafenib plus trametinib in patients with BRAFV600-mutant melanoma brain metastases (COMBI-MB): a multicentre, multicohort, open-label, phase 2 trial. Lancet Oncol. 2017 07; 18(7):863-873.
Score: 0.094
-
Tumor genetic analyses of patients with metastatic melanoma treated with the BRAF inhibitor dabrafenib (GSK2118436). Clin Cancer Res. 2013 Sep 01; 19(17):4868-78.
Score: 0.072
-
Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Nov; 13(11):1087-95.
Score: 0.068
-
Clinical, Molecular, and Immune Analysis of Dabrafenib-Trametinib Combination Treatment for BRAF Inhibitor-Refractory Metastatic Melanoma: A Phase 2 Clinical Trial. JAMA Oncol. 2016 Aug 01; 2(8):1056-64.
Score: 0.022